Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: Results from the randomized, placebo-controlled Phase III INVIGORATE-2 study
Arthritis Rheumatol 2024 doi: 10.1002/art.42997
IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.